HRP20010949B1 - Antipsychotic cyclin n-aralkyl amines - Google Patents

Antipsychotic cyclin n-aralkyl amines

Info

Publication number
HRP20010949B1
HRP20010949B1 HR20010949A HRP20010949A HRP20010949B1 HR P20010949 B1 HRP20010949 B1 HR P20010949B1 HR 20010949 A HR20010949 A HR 20010949A HR P20010949 A HRP20010949 A HR P20010949A HR P20010949 B1 HRP20010949 B1 HR P20010949B1
Authority
HR
Croatia
Prior art keywords
group
hydrogen
phenyl
methyl
atom
Prior art date
Application number
HR20010949A
Other languages
English (en)
Croatian (hr)
Inventor
Boigegrain Robert
Bourrie Martine
Lair Pierre
Paul Raymond
Poncelet Martine
Vernieres Jean-Claude
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of HRP20010949A2 publication Critical patent/HRP20010949A2/hr
Publication of HRP20010949B1 publication Critical patent/HRP20010949B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20010949A 1999-07-02 2001-12-21 Antipsychotic cyclin n-aralkyl amines HRP20010949B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9908532A FR2795724B1 (fr) 1999-07-02 1999-07-02 Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
PCT/FR2000/001790 WO2001002380A1 (fr) 1999-07-02 2000-06-27 N-aralkyl amines cycliques antipsychotiques

Publications (2)

Publication Number Publication Date
HRP20010949A2 HRP20010949A2 (en) 2003-04-30
HRP20010949B1 true HRP20010949B1 (en) 2006-06-30

Family

ID=9547628

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010949A HRP20010949B1 (en) 1999-07-02 2001-12-21 Antipsychotic cyclin n-aralkyl amines

Country Status (31)

Country Link
US (1) US6908914B1 (pt)
EP (1) EP1196403B1 (pt)
JP (1) JP4931309B2 (pt)
KR (1) KR100760446B1 (pt)
CN (1) CN1156462C (pt)
AR (1) AR029374A1 (pt)
AT (1) ATE309231T1 (pt)
AU (1) AU778299B2 (pt)
BG (1) BG65209B1 (pt)
BR (1) BR0012463B1 (pt)
CA (1) CA2376691C (pt)
CO (1) CO5021196A1 (pt)
CZ (1) CZ300936B6 (pt)
DE (1) DE60023898T2 (pt)
DK (1) DK1196403T3 (pt)
EA (1) EA004048B1 (pt)
ES (1) ES2250160T3 (pt)
FR (1) FR2795724B1 (pt)
HK (1) HK1043122A1 (pt)
HR (1) HRP20010949B1 (pt)
HU (1) HU228983B1 (pt)
IL (2) IL147069A0 (pt)
ME (1) MEP25508A (pt)
MX (1) MXPA01013207A (pt)
NO (1) NO322230B1 (pt)
NZ (1) NZ516342A (pt)
RS (1) RS50266B (pt)
TW (1) TWI285640B (pt)
UA (1) UA71009C2 (pt)
WO (1) WO2001002380A1 (pt)
ZA (1) ZA200200018B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1420644B1 (de) * 2001-08-23 2006-05-31 Bayer CropScience S.A. Substituierte propargylamine
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790971A (fr) * 1971-11-09 1973-05-07 Janssen Pharmaceutica Nv Metode ter voorkoming van patologische reakties die de funktie van het komplement vereisen
JPS504086A (pt) * 1973-01-18 1975-01-16
US4104383A (en) * 1973-11-02 1978-08-01 C M Industries Derivatives of phenylpropenylamine
GB1475314A (en) * 1973-11-02 1977-06-01 Cm Ind Phenyl-propylamine derivatives
US4855462A (en) * 1988-06-17 1989-08-08 Pennwalt Corporation Antihistamines
US4912222A (en) * 1988-06-17 1990-03-27 Fisons Corporation Antihistamines related to cyproheptadine
EP0347123A3 (en) * 1988-06-17 1991-07-03 Fisons Corporation Dibenzo-cycloheptenyl, -cycloheptyl and -oxepinyl amines having antihistaminic properties
FR2663328B1 (fr) 1990-06-14 1994-08-05 Sanofi Sa Derives d'hexahydroazepines, un procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH06509069A (ja) * 1991-06-27 1994-10-13 バージニア・コモンウェルス・ユニバーシティ シグマレセプターリガンドおよびその用途
JP3199405B2 (ja) * 1991-08-30 2001-08-20 生化学工業株式会社 肝細胞球状集塊化剤及び球状集塊化肝細胞の製造方法
US5486517A (en) * 1994-05-10 1996-01-23 Warner-Lambert Company Benzimidazoles and imidazopyridines as central nervous system agents
FR2751645B1 (fr) * 1996-07-29 1998-12-24 Sanofi Sa Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales
CN1183116C (zh) * 1997-03-18 2005-01-05 史密丝克莱恩比彻姆有限公司 取代的异喹啉类衍生物、含有它们的药物组合物、其制备方法及用途

Also Published As

Publication number Publication date
CN1367783A (zh) 2002-09-04
NO20016392D0 (no) 2001-12-27
NZ516342A (en) 2003-08-29
MEP25508A (en) 2010-06-10
RS50266B (sr) 2009-07-15
FR2795724B1 (fr) 2002-12-13
NO322230B1 (no) 2006-08-28
KR20020016877A (ko) 2002-03-06
EP1196403A1 (fr) 2002-04-17
YU91101A (sh) 2004-09-03
AU778299B2 (en) 2004-11-25
DK1196403T3 (da) 2006-03-20
AR029374A1 (es) 2003-06-25
KR100760446B1 (ko) 2007-10-04
NO20016392L (no) 2002-03-04
AU5992400A (en) 2001-01-22
UA71009C2 (uk) 2004-11-15
HU228983B1 (en) 2013-07-29
CO5021196A1 (es) 2001-03-27
MXPA01013207A (es) 2002-06-21
ATE309231T1 (de) 2005-11-15
EP1196403B1 (fr) 2005-11-09
BG106255A (en) 2002-10-31
EA004048B1 (ru) 2003-12-25
CZ300936B6 (cs) 2009-09-16
BR0012463B1 (pt) 2014-11-04
CZ20014697A3 (cs) 2002-04-17
ES2250160T3 (es) 2006-04-16
FR2795724A1 (fr) 2001-01-05
CN1156462C (zh) 2004-07-07
HK1043122A1 (zh) 2002-09-06
JP2003503487A (ja) 2003-01-28
DE60023898T2 (de) 2006-08-10
BG65209B1 (bg) 2007-07-31
CA2376691A1 (en) 2001-01-11
CA2376691C (en) 2009-09-01
PL356186A1 (en) 2004-06-14
DE60023898D1 (de) 2005-12-15
HUP0202200A3 (en) 2002-12-28
BR0012463A (pt) 2002-04-02
ZA200200018B (en) 2003-01-02
TWI285640B (en) 2007-08-21
US6908914B1 (en) 2005-06-21
IL147069A (en) 2006-09-05
WO2001002380A8 (fr) 2001-06-28
WO2001002380A1 (fr) 2001-01-11
EA200101209A1 (ru) 2002-06-27
JP4931309B2 (ja) 2012-05-16
IL147069A0 (en) 2002-08-14
HUP0202200A2 (en) 2002-10-28
HRP20010949A2 (en) 2003-04-30

Similar Documents

Publication Publication Date Title
RS49998B (sr) Derivati benzena, postupak za njihovo dobijanje i farmaceutski preparati koji ih sadrže
NZ536734A (en) Spiroindolinepiperidine derivatives
MY141255A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
RS20060041A (en) Carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists
MXPA04001016A (es) Derivados de sulfonamida como inhibidores de la gamma secretasa.
PT1585739E (pt) Arilciclopropilacetamidas substitu?das como activadores da glucocinase
RS20050329A (en) Selected cgrp antagonists,method for production and use thereof as medicament
GB0129476D0 (en) Organic compounds
EP1679069A4 (en) NEW PIPERIDINE DERIVATIVE
HRP20070529T3 (en) Imidazole derivatives as glutmate receptor antagonists
TW200726470A (en) 6,7-unsaturated-7-carbamoylmorphinan derivatives
MXPA05011411A (es) 1,4-diazepinas sustituidas y usos de las mismas.
RS51200B (sr) (imidazol-1-il-metil)-piridazin kao blokator nmda receptora
TW200505852A (en) Novel compounds
TW200616636A (en) Novel compounds
TW200626145A (en) Heterocyclic compounds and thrombopoietin receptor activators
HRP20010949B1 (en) Antipsychotic cyclin n-aralkyl amines
EA200500683A1 (ru) Новые соединения пирролидина и тиазолидина, способ их получения и фармацевтические композиции, которые их содержат
HRP20060023A2 (en) Use of bicyclo[2.2.1]heptane derivatives for the preparation of neuroprotective pharmaceutical compositions
TW200505446A (en) Inhibitor of cox
AR044175A1 (es) Compuestos de cefemo
HRP20020440B1 (en) 1-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
HRP20050617A2 (en) Imidazol derivatives having affinity for alpha 2 receptors activity
CA2466728A1 (en) Azetidinyl diamines useful as ligands of the nociceptin receptor orl-1
WO2002017954A1 (fr) Medicaments contre la maladie de parkinson

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: SANOFI-AVENTIS, FR

B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20130506

Year of fee payment: 14

PBON Lapse due to non-payment of renewal fee

Effective date: 20140627